Ekamol Tantisattamo1, Ramy M Hanna, Uttam G Reddy, Hirohito Ichii, Donald C Dafoe, Gabriel M Danovitch, Kamyar Kalantar-Zadeh. 1. Harold Simmons Center for Kidney Disease Research and Epidemiology, Division of Nephrology, Hypertension and Kidney Transplantation, Department of Medicine, University of California Irvine School of Medicine, Orange Nephrology Section, Department of Medicine, Veterans Affairs Long Beach Healthcare System, Long Beach, California Section of Nephrology, Department of Internal Medicine, Multi-Organ Transplant Center, William Beaumont Hospital, Oakland University William Beaumont School of Medicine, Royal Oak, Michigan Division of Kidney and Pancreas Transplantation, Department of Surgery, University of California Irvine School of Medicine, Orange, California Division of Nephrology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA.
Abstract
PURPOSE OF REVIEW: Despite improvement in short-term renal allograft survival in recent years, renal transplant recipients (RTR) have poorer long-term allograft outcomes. Allograft function slowly declines with periods of stable function similar to natural progression of chronic kidney disease in nontransplant population. Nearly all RTR transitions to failing renal allograft (FRG) period and require transition to dialysis. Conservative chronic kidney disease management before transition to end-stage renal disease is an increasingly important topic; however, there is limited data in RTR regarding how to delay dialysis initiation with conservative management. RECENT FINDINGS: Since immunological and nonimmunological factors unique to RTR contribute to decline in allograft function, therapies to slow progression of FRG should take both sets of factors into account. Renal replacement therapy either incremental dialysis or rekidney transplantation should be explored. This required taking benefits and risks of continuing immunosuppressive medications into account when allograft nephrectomy may be necessary. SUMMARY: FRG may benefit from various interventions to slow progression of worsening allograft function. Until there are stronger evidence to guide interventions to preserve renal function, extrapolating evidence from nontransplant patients and clinical judgment are necessary. The goal is to provide individualized care for conservative management of RTR with FRG.
PURPOSE OF REVIEW: Despite improvement in short-term renal allograft survival in recent years, renal transplant recipients (RTR) have poorer long-term allograft outcomes. Allograft function slowly declines with periods of stable function similar to natural progression of chronic kidney disease in nontransplant population. Nearly all RTR transitions to failing renal allograft (FRG) period and require transition to dialysis. Conservative chronic kidney disease management before transition to end-stage renal disease is an increasingly important topic; however, there is limited data in RTR regarding how to delay dialysis initiation with conservative management. RECENT FINDINGS: Since immunological and nonimmunological factors unique to RTR contribute to decline in allograft function, therapies to slow progression of FRG should take both sets of factors into account. Renal replacement therapy either incremental dialysis or rekidney transplantation should be explored. This required taking benefits and risks of continuing immunosuppressive medications into account when allograft nephrectomy may be necessary. SUMMARY: FRG may benefit from various interventions to slow progression of worsening allograft function. Until there are stronger evidence to guide interventions to preserve renal function, extrapolating evidence from nontransplant patients and clinical judgment are necessary. The goal is to provide individualized care for conservative management of RTR with FRG.
Authors: Gabriel Choukroun; Nassim Kamar; Bertrand Dussol; Isabelle Etienne; Elisabeth Cassuto-Viguier; Olivier Toupance; François Glowacki; Bruno Moulin; Yvon Lebranchu; Guy Touchard; Maïté Jaureguy; Nicolas Pallet; Yannick Le Meur; Lionel Rostaing; Frank Martinez Journal: J Am Soc Nephrol Date: 2011-12-22 Impact factor: 10.121
Authors: E Lars Penne; Neelke C van der Weerd; Muriel P C Grooteman; Albert H A Mazairac; Marinus A van den Dorpel; Menso J Nubé; Michiel L Bots; Renée Lévesque; Piet M ter Wee; Peter J Blankestijn Journal: Clin J Am Soc Nephrol Date: 2010-10-28 Impact factor: 8.237
Authors: Javier Varas; María José Pérez-Sáez; Rosa Ramos; Jose Ignacio Merello; Angel Luis M de Francisco; José Luño; Manuel Praga; Pedro Aljama; Julio Pascual Journal: Nephrol Dial Transplant Date: 2019-04-01 Impact factor: 5.992
Authors: Tariq Shafi; Bernard G Jaar; Laura C Plantinga; Nancy E Fink; John H Sadler; Rulan S Parekh; Neil R Powe; Josef Coresh Journal: Am J Kidney Dis Date: 2010-06-03 Impact factor: 8.860
Authors: Fabian Termorshuizen; Johanna C Korevaar; Friedo W Dekker; Jeannette G van Manen; Elisabeth W Boeschoten; Raymond T Krediet Journal: Am J Kidney Dis Date: 2003-06 Impact factor: 8.860